How to get Strattera fast in California

If you’re exploring treatment options for ADHD, you’ve likely wondered: Can I get non-stimulant ADHD medication prescribed through telehealth? The short answer is yes—and for many people, it’s become a convenient, accessible way to manage symptoms without the strict regulations that apply to stimulant medications.

Non-stimulant ADHD medications like Strattera (atomoxetine) offer an alternative for patients who can’t tolerate stimulants, have a history of substance use concerns, or simply prefer a non-controlled treatment option. Unlike stimulant medications such as Adderall or Vyvanse, Strattera is not a controlled substance, which means it’s not subject to the same federal prescribing restrictions—and that makes telehealth prescribing more straightforward.

In this guide, we’ll walk you through everything you need to know about getting non-stimulant ADHD medication via telehealth in 2025, including how the process works, what to expect during your evaluation, state-by-state rules, and how services like Klarity Health are helping patients access quality care from the comfort of home.

Understanding Non-Stimulant ADHD Medications

What Are Non-Stimulant ADHD Medications?

Non-stimulant medications work differently than traditional ADHD stimulants. While stimulants like Adderall increase dopamine and norepinephrine levels quickly, non-stimulants take a gentler approach—often targeting norepinephrine alone and requiring several weeks to reach full effectiveness.

Strattera (atomoxetine) is the most commonly prescribed non-stimulant for ADHD. It’s FDA-approved for children (ages 6+), teens, and adults. Because it’s not classified as a controlled substance by the DEA, Strattera carries no risk of dependency or abuse, making it an attractive option for many patients.

Why Choose a Non-Stimulant?

You might consider a non-stimulant ADHD medication if you:

• Have a history of substance use disorder or anxiety about stimulant dependency
• Experience uncomfortable side effects from stimulants (like increased heart rate, appetite suppression, or sleep disturbances)
• Have co-occurring conditions such as anxiety or tics that stimulants may worsen
• Prefer a medication that provides steady, all-day symptom control without ‘peaks and valleys’
• Need a longer prescription supply (non-stimulants can often be prescribed for 90 days with refills, unlike stimulants which require monthly prescriptions)

While non-stimulants like Strattera may take 4–6 weeks to show full benefits (compared to stimulants that work within hours), many patients find them highly effective—especially when combined with therapy, coaching, or lifestyle modifications.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

How Telehealth ADHD Treatment Works

The Evaluation Process

Getting ADHD medication through telehealth isn’t as simple as filling out an online quiz. Legitimate telehealth providers follow the same rigorous diagnostic criteria used in traditional in-person care, based on DSM-5 guidelines.

Here’s what a typical telehealth ADHD evaluation involves:

1. Initial Intake and Screening
You’ll complete detailed questionnaires about your symptoms, medical history, and how ADHD affects your daily life—at work, school, home, and in relationships. Many providers use standardized ADHD rating scales to assess symptom severity.

2. Live Video Consultation
A licensed clinician (physician, psychiatrist, or psychiatric nurse practitioner) will conduct a comprehensive video evaluation. They’ll ask about:

• When your symptoms started (ADHD symptoms must be present before age 12)
• How symptoms manifest in different settings
• Past treatments or medications you’ve tried
• Family history of ADHD or mental health conditions
• Any co-occurring conditions (depression, anxiety, learning disabilities)
• Substance use history
• Current medications and health conditions

3. Diagnosis and Treatment Plan
If the provider determines you meet criteria for ADHD, they’ll discuss treatment options—which may include medication, therapy, lifestyle changes, or a combination. For non-stimulant medications like Strattera, they’ll explain:

• How the medication works
• Expected timeline for benefits (typically 4–6 weeks)
• Potential side effects (nausea, fatigue, decreased appetite, mood changes)
• Monitoring requirements (blood pressure, heart rate, liver function)
• FDA warnings (Strattera carries a black box warning for increased suicidal thoughts in children and adolescents)

4. E-Prescription and Follow-Up
If Strattera is appropriate, your provider will send an electronic prescription directly to your pharmacy. You’ll schedule follow-up appointments (often after 2–4 weeks, then monthly or quarterly) to monitor progress, adjust dosing if needed, and address any concerns.

What Makes Telehealth Prescribing Different?

Because the provider can’t conduct a physical exam, they rely more heavily on your self-reported history and may request:

• Previous medical records
• School records or report cards (especially for young adults never formally diagnosed)
• Input from family members who can confirm symptom patterns
• Proof of identity and location (to ensure proper state licensure)

Reputable telehealth platforms have tightened their protocols significantly since 2023, following regulatory scrutiny of online ADHD prescribing practices. Expect thorough evaluations—providers take diagnostic accuracy and patient safety seriously.

Federal Rules: Why Non-Stimulants Are Easier to Prescribe via Telehealth

The DEA Controlled Substance Distinction

Here’s the key regulatory difference: Strattera is not a DEA-controlled substance. The federal Ryan Haight Act—which normally requires an in-person medical evaluation before prescribing controlled substances online—doesn’t apply to non-controlled medications like Strattera.

This means there’s no federal law requiring you to have an in-person visit before receiving a Strattera prescription via telehealth. A licensed provider can evaluate you entirely through video and legally prescribe the medication if clinically appropriate.

What About Stimulant Medications?

The situation is more complex for ADHD stimulants (Schedule II controlled substances like Adderall, Ritalin, or Vyvanse). During the COVID-19 pandemic, the DEA issued temporary waivers allowing telehealth prescribing of controlled substances without prior in-person exams.

Current Status (December 2025): The DEA’s ‘Third Temporary Extension’ allows continued telehealth prescribing of Schedule II–V controlled substances through December 31, 2025. A fourth extension for 2026 is under review but not yet finalized. If the waivers expire without replacement, the original Ryan Haight Act requirements—including mandatory in-person exams for controlled substance prescriptions—could return.

For patients considering stimulant medications, this regulatory uncertainty makes planning important. Non-stimulants like Strattera offer more stability—they’re not subject to these changing federal rules.

Proposed DEA Special Registration

The DEA proposed a ‘Special Registration’ rule in early 2025 that would create a permanent framework for telehealth controlled substance prescribing with additional safeguards. This rule hasn’t been finalized, and experts don’t expect implementation until late 2025 or 2026 at the earliest.

State-by-State Telehealth Rules for ADHD Treatment

While federal law sets the baseline, state regulations govern actual practice. Here’s what you need to know about key states:

States with No Special Restrictions

California, Illinois, Pennsylvania, and Georgia don’t impose extra in-person visit requirements for telehealth ADHD care. As long as your provider is licensed in your state and follows standard-of-care guidelines, you can receive non-stimulant prescriptions entirely through telehealth.

California’s AB 1503 (pending in 2025) aims to further clarify that telehealth evaluations constitute valid ‘prior exams’ for prescribing purposes—reinforcing the state’s telehealth-friendly approach.

States with Recent Expansions

New Hampshire (August 2025): SB 252 eliminated the previous in-person requirement for controlled substance prescriptions via telehealth. Providers now only need to conduct at least one annual follow-up evaluation (which can be done via telehealth) for ongoing controlled medication treatment. This significantly expanded access for NH residents seeking ADHD care online.

States with Stricter Requirements

New York (May 2025): New York implemented a final rule requiring an initial in-person medical evaluation before prescribing any controlled substance via telehealth. This affects patients seeking stimulant medications but doesn’t impact Strattera prescriptions since it’s not controlled.

Florida: Generally prohibits telehealth prescribing of Schedule II medications unless prescribed for a psychiatric condition (ADHD qualifies), or the patient is hospitalized, in hospice, or a nursing facility. Florida law requires providers to check the state Prescription Drug Monitoring Program (PDMP) before every controlled substance prescription. For non-controlled Strattera, these restrictions don’t apply.

Alabama: Requires an in-person visit within 12 months for ongoing telehealth treatment of most conditions (with exceptions for mental health services). Alabama also mandates that a licensed medical professional be physically present with the patient during telehealth visits for initial controlled substance prescriptions. These rules primarily affect stimulant prescribing; mental health telehealth (including ADHD psychiatric care) has more flexibility.

Texas: Very telehealth-friendly for mental health services, including ADHD treatment. However, Texas law restricts nurse practitioners and physician assistants from prescribing Schedule II medications (like stimulants) outside of hospital or hospice settings—physicians have broader prescribing authority. For Strattera and other non-controlled medications, NPs and PAs can prescribe under their collaborative practice agreements.

Who Can Prescribe ADHD Medications via Telehealth?

Physicians (MD/DO)

In all states, licensed physicians can prescribe both stimulant and non-stimulant ADHD medications via telehealth, provided they hold appropriate state licenses and DEA registrations for controlled substances.

Nurse Practitioners (NP) and Physician Assistants (PA)

Prescribing authority for NPs and PAs varies significantly by state:

Full Practice Authority States (e.g., New York, Illinois, New Hampshire, California): NPs can practice independently and prescribe all medication schedules, including Schedule II stimulants, after meeting experience requirements (typically 2,000–4,000 supervised practice hours). PAs generally require collaborative agreements but have broad prescribing authority.

Collaborative Practice States (e.g., Florida, Pennsylvania, Alabama): NPs and PAs must work under physician supervision or collaborative agreements. They can prescribe non-controlled medications like Strattera but face various restrictions on controlled substances depending on state law.

Restricted States (e.g., Texas, Georgia): These states significantly limit or prohibit NP/PA prescribing of Schedule II medications. In Texas, NPs can only prescribe stimulants in hospital or hospice settings. In Georgia, NPs cannot prescribe Schedule II drugs at all, even with physician delegation.

For non-stimulant medications like Strattera: NPs and PAs in all states can prescribe under their scope of practice (with collaborative agreements where required), making telehealth access relatively consistent nationwide.

Prescription Monitoring Programs and Safety Checks

PDMP Requirements

Prescription Drug Monitoring Programs (PDMPs) are state-run databases tracking controlled substance prescriptions. Most states now mandate providers check these databases before prescribing certain medications.

For Strattera specifically: Since it’s not a controlled substance, PDMP checks aren’t legally required in any state. However, responsible providers often review patients’ medication histories as part of comprehensive care—especially to identify any potential drug interactions or patterns suggesting medication misuse.

For stimulant medications: PDMP check requirements vary:

• Florida: Every prescription
• California: At least every 4 months for ongoing therapy
• Pennsylvania, New Hampshire, Alabama: Before first prescription and at regular intervals (typically 90 days)
• Texas: Required for opioids, benzodiazepines, barbiturates, and carisoprodol—but notably not for stimulants (though many providers check anyway)

Enhanced Screening Post-2023

Following regulatory investigations into several large telehealth ADHD companies in 2022–2023, the industry has implemented stricter safety protocols. Legitimate telehealth providers now commonly:

• Conduct more thorough diagnostic evaluations
• Require video visits (not just phone calls) for controlled substances
• Verify patient identity and location
• Coordinate with primary care providers when appropriate
• Schedule regular follow-ups to monitor treatment response
• Screen for substance use history and contraindications
• Provide patient education about proper medication use

These safeguards protect both patients and providers while ensuring continued access to telehealth ADHD care.

Common Questions and Misconceptions

‘Can I really get legitimate ADHD medication online?’

Yes—when working with licensed, reputable telehealth providers who follow proper diagnostic and prescribing protocols. The key is choosing platforms that require comprehensive evaluations, use licensed clinicians, and maintain rigorous standards of care.

Services like Klarity Health connect patients with board-certified providers who are licensed in their state, conduct thorough video evaluations, and follow evidence-based treatment guidelines. Klarity offers transparent pricing (accepting both insurance and cash pay), and importantly, their providers are typically available for appointments within days rather than the weeks or months you might wait for a traditional psychiatrist.

‘Will pharmacies fill telehealth prescriptions?’

Generally, yes. Electronic prescriptions are standard practice, and pharmacies don’t differentiate between telehealth and in-person visits when processing legitimate prescriptions from licensed providers.

Some pharmacies did increase scrutiny of telehealth stimulant prescriptions in 2023 following media coverage of questionable prescribing practices. Using established telehealth services and maintaining consistency with one pharmacy can help avoid any issues.

For Strattera specifically, pharmacy acceptance is rarely a concern since it’s not a controlled substance.

‘Non-stimulants don’t work as well as stimulants’

This is a misconception. While non-stimulants work differently (and more gradually) than stimulants, research shows they can be highly effective for many patients. Studies indicate approximately 60–70% of patients respond well to Strattera, with meaningful symptom improvement in attention, impulse control, and hyperactivity.

Non-stimulants offer unique advantages:

• No risk of dependency or abuse
• Steady 24-hour symptom coverage (no ‘wearing off’ in evening)
• Can be prescribed with refills and longer supplies
• May be better tolerated by patients with anxiety or tics
• No concerns about stimulant-related cardiovascular effects

The ‘best’ ADHD medication is the one that works for your specific symptoms, health profile, and lifestyle—not necessarily the most commonly prescribed option.

‘Telehealth ADHD treatment is just a quick prescription’

Not at all. Legitimate telehealth ADHD care involves the same comprehensive evaluation, ongoing monitoring, and treatment adjustments as traditional in-person care. Providers must document thorough symptom assessment, rule out alternative diagnoses, discuss risks and benefits, and create a treatment plan that may include therapy, coaching, or lifestyle modifications—not just medication.

Expect your initial telehealth ADHD evaluation to take 45–90 minutes, with regular follow-up appointments to ensure treatment effectiveness and safety.

Patient Eligibility and Contraindications

Who Is a Good Candidate for Telehealth ADHD Treatment?

Telehealth works well for:

• Adults with stable ADHD symptoms seeking treatment
• Patients who have difficulty accessing in-person psychiatric care due to long wait times, transportation challenges, or living in underserved areas
• People with previously diagnosed ADHD seeking continued treatment or medication management
• Individuals without complex co-occurring conditions that require in-person evaluation

Who Should Seek In-Person Care?

Telehealth may not be appropriate if you have:

• Unstable or severe mental health conditions (uncontrolled bipolar disorder, active psychosis, acute suicidality)
• Serious cardiovascular disease requiring careful in-person monitoring
• History of substance use disorder requiring specialized addiction treatment
• Complex medical conditions requiring physical examination
• Young children (most telehealth platforms treat ages 18+, though some accept teens with parent involvement)

Strattera-Specific Contraindications

Your provider will screen for conditions that make Strattera unsafe or less appropriate:

• Absolute contraindications: Narrow-angle glaucoma; current or recent (within 14 days) MAOI antidepressant use; known hypersensitivity to atomoxetine
• Relative contraindications: Severe cardiovascular disease; hypertension; tachycardia; liver disease; history of seizures; urinary retention

If Strattera isn’t suitable, your provider may discuss other non-stimulants like Qelbree (viloxazine), guanfacine (Intuniv), or clonidine (Kapvay)—or refer you for in-person evaluation if stimulant medications are needed but telehealth isn’t appropriate for your situation.

What to Expect: The Strattera Experience

Timeline and Effectiveness

Unlike stimulants that provide noticeable effects within hours, Strattera requires patience:

• Week 1–2: Side effects (usually mild nausea, fatigue, decreased appetite) are most common as your body adjusts. Taking Strattera with food can help minimize nausea.
• Week 3–4: Some patients begin noticing subtle improvements in focus and impulse control.
• Week 6–8: Full therapeutic effects typically emerge. You may notice better sustained attention, reduced impulsivity, improved task completion, and better emotional regulation.

Your provider will likely start with a low dose and gradually increase to find your optimal therapeutic level—usually 40–100 mg daily for adults (can go up to 100 mg/day or 1.4 mg/kg body weight).

Common Side Effects

Most side effects are mild and temporary:

• Decreased appetite and modest weight loss
• Nausea or upset stomach (often improves after first few weeks)
• Fatigue or drowsiness (can also cause insomnia in some patients—timing of dose may need adjustment)
• Dry mouth
• Constipation
• Decreased libido or sexual side effects

Serious Warnings

Strattera carries FDA black box warnings for:

• Suicidal thoughts: Increased risk in children and adolescents, particularly in the first few months of treatment. Close monitoring is essential—immediately report any worsening mood, unusual changes in behavior, or suicidal thoughts.
• Liver injury: Rare but serious. Report yellowing of skin/eyes, dark urine, upper right abdominal pain, or unexplained flu-like symptoms immediately.
• Cardiovascular effects: Can increase heart rate and blood pressure. Your provider should monitor these regularly, especially if you have pre-existing heart conditions.

Monitoring and Follow-Up

Expect your telehealth provider to:

• Schedule follow-up within 2–4 weeks of starting Strattera
• Ask about side effects and symptom improvement
• Check blood pressure and heart rate (you may need a home monitor or visit to local clinic/pharmacy)
• Adjust dosing based on response and tolerability
• Continue regular follow-ups (monthly initially, then quarterly once stable)

Your provider may also recommend periodic blood tests to monitor liver function, especially if you have risk factors or develop symptoms suggesting liver problems.

Making Telehealth ADHD Treatment Work for You

Choose a Reputable Provider

Look for telehealth platforms that:

• Use licensed, board-certified physicians or psychiatric specialists
• Require comprehensive video evaluations (not just questionnaires)
• Follow DSM-5 diagnostic criteria
• Provide ongoing care and follow-up (not just one-time prescriptions)
• Offer transparent pricing and accept insurance
• Coordinate with your other healthcare providers when appropriate

Klarity Health meets all these criteria, connecting patients with experienced psychiatric providers for thorough ADHD evaluations and ongoing treatment. With both insurance and affordable cash-pay options, Klarity makes quality mental healthcare accessible—often with appointments available within days rather than months.

Be Honest and Thorough

Your provider can only help if they have accurate information. During your evaluation:

• Describe symptoms candidly, including how they impact work, relationships, and daily functioning
• Disclose all medications, supplements, and substances you use
• Share relevant medical and psychiatric history
• Mention any past medication trials—what worked, what didn’t, and why
• Discuss concerns about side effects or medication types

Remember, providers aren’t there to judge—they need complete information to develop the safest, most effective treatment plan.

Stay Engaged in Treatment

Successful ADHD management involves more than just medication:

• Attend all follow-up appointments
• Communicate side effects or concerns promptly
• Track your symptoms and progress (many apps can help)
• Consider complementary approaches: therapy (especially CBT for ADHD), coaching, organizational skills training, sleep optimization, exercise
• Give medications adequate time to work—don’t give up on Strattera after just 2 weeks
• Never adjust doses or stop medication without consulting your provider

Know Your Rights and Responsibilities

As a telehealth patient, you should:

• Receive the same standard of care as in-person visits
• Have your privacy protected (HIPAA applies to telehealth)
• Get clear information about diagnosis, treatment options, risks, and benefits
• Be able to ask questions and have them answered
• Switch providers if you’re not satisfied with care

You’re also responsible to:

• Use medication only as prescribed
• Store medication securely (even though Strattera isn’t controlled, keep it away from children and others)
• Follow up regularly for monitoring
• Be honest about your treatment experience
• Inform your provider if you move to a new state (may require finding a provider licensed there)

Looking Ahead: The Future of Telehealth ADHD Treatment

Regulatory Outlook

The telehealth landscape continues to evolve:

DEA Rules: The current temporary extension for controlled substance telehealth prescribing expires December 31, 2025. While a fourth extension is expected, long-term regulations remain under development. The proposed ‘Special Registration’ system could create permanent telehealth pathways with additional provider requirements and patient safeguards.

State Laws: More states are moving toward permanent telehealth expansions (like New Hampshire’s 2025 reforms) while implementing appropriate guardrails. Expect continued state-by-state variation, with some states embracing telehealth and others maintaining stricter in-person requirements.

For non-stimulants like Strattera: Regulatory uncertainty primarily affects stimulant medications. Non-stimulant telehealth prescribing should remain stable and widely accessible regardless of DEA rule changes.

What This Means for Patients

If you’re currently receiving or considering telehealth ADHD treatment:

• Stay informed: Your provider should notify you of any relevant regulatory changes
• Have a backup plan: If you’re on stimulant medications, discuss with your provider what would happen if in-person requirements return
• Consider non-stimulants: For some patients, switching to medications like Strattera provides more long-term stability given regulatory uncertainties
• Build relationships: Establishing care with a consistent provider (whether telehealth or hybrid) ensures continuity even if rules change

The Role of Platforms Like Klarity Health

Services like Klarity Health are adapting to regulatory changes while maintaining accessible, high-quality care. By connecting patients with licensed providers, using secure technology, implementing rigorous safety protocols, and staying current on all regulatory requirements, platforms like Klarity help ensure you can continue receiving the ADHD treatment you need—whether that’s through pure telehealth or hybrid models combining video visits with periodic in-person care.

With transparent pricing, insurance acceptance, and provider availability that far exceeds traditional psychiatry wait times, Klarity makes getting help for ADHD more feasible for busy adults who’ve struggled to find care.

Conclusion: Accessible ADHD Care Is Here

Getting non-stimulant ADHD medication through telehealth is not only possible—it’s often the most practical option for adults seeking diagnosis and treatment in 2025. Strattera and other non-stimulant medications offer effective symptom management without the regulatory complexity and dependency concerns of stimulant medications.

Telehealth has democratized access to psychiatric care, breaking down barriers of geography, scheduling, and stigma. Whether you’ve struggled to find a local psychiatrist, suspect you have undiagnosed ADHD that’s impacting your career or relationships, or simply need a more convenient way to manage ongoing treatment, legitimate telehealth services provide a path forward.

The key is working with reputable providers who take diagnosis seriously, follow evidence-based treatment protocols, and provide ongoing support—not just quick prescriptions. With proper evaluation, monitoring, and patient engagement, telehealth ADHD treatment can be just as effective as traditional in-person care, often with significantly better access.

If you’re ready to take the next step in managing your ADHD symptoms, consider exploring telehealth options like Klarity Health. With experienced providers, streamlined scheduling, and both insurance and cash-pay options, you could be on your way to clearer thinking, better focus, and improved quality of life—often within days of your first appointment.

References

1. FierceHealthcare. ‘DEA finalizes one-year extension of controlled substance prescribing via telehealth.’ November 2024. https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final

2. McDermott Will & Emery. ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026.’ 2025. https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/

3. Sheppard Mullin Healthcare Law Blog. ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions.’ August 15, 2025. https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/

4. Medical News Today. ‘Is Strattera a controlled substance?’ January 14, 2025. https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance

5. Center for Connected Health Policy. ‘Online Prescribing.’ 2025. https://www.cchpca.org/topic/online-prescribing/

Research verified as of December 17, 2025. Federal telehealth flexibilities for controlled substances extended through December 31, 2025. State-specific information confirmed via sources dated 2025 or later where available.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment